Mesenchymal stem cells in autoimmune diseases: hype or hope?
Intervention with mesenchymal stem cells (MSCs) represents a promising therapeutic tool in treatment-refractory autoimmune diseases. A new report by Schurgers and colleagues in a previous issue of Arthritis Research & Therapy sheds novel mechanistic insight into the pathways employed by MSCs to suppress T-cell proliferation in vitro, but, at the same time, indicates that MSCs do not influence T-cell reactivity and the disease course in an in vivo arthritis model. Such discrepancies between the in vitro and in vivo effects of potent cellular immune modulators should spark further research and should be interpreted as a sign of caution for the in vitro design of MSC-derived interventions in the setting of human autoimmune diseases.
Scherer
Hans U
HU
van Pel
Melissa
M
Toes
René E M
RE
D000818:Animals; D001169:Arthritis, Experimental / Q000503:physiopathology / Q000601:surgery; D001327:Autoimmune Diseases / Q000503:physiopathology* / Q000601:surgery*; D049109:Cell Proliferation; D004195:Disease Models, Animal; D006086:Graft vs Host Disease / Q000503:physiopathology; D006801:Humans; D056747:Immunomodulation / Q000502:physiology; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D051379:Mice; D013601:T-Lymphocytes / Q000473:pathology